TGen Research - Investigators and Advisors - Daniel Von Hoff, M.D., F.A.C.P.

Research Faculty


	Profile


	Selected Publications


	The Pancreatic Cancer Research Team

Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD. UA62784, a novel inhibitor of centromere protein E kinesin-like protein Mol Cancer Ther, Jan;8(1):36-44. 2009.

Wang H, Stephens B, Von Hoff DD, Han H. Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells Pancreas, Jul;38(5):551-7. 2009.

Colvin J, Monine MI, Faeder JR, Hlavacek WS, Von Hoff DD, Posner RG. Simulation of large-scale rule-based models Bioinformatics, 1;25(7) 910-917. 2009.

Azorsa, D.O., Gonzales I.M., Basu, G.D., Choudhary, A., Arora, S., Bisanz, K.M., Kiefer, J.A., Henderson, M.C., Trent, J.M., Von Hoff, D.D., and Mousses, S.. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Trans Med, 7:43. 2009.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad M,J, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA. Inhibition of the Hedgehog Pathway in Advanced Basal Cell Carcinoma. N Engl J Med, 17;361(12):1164-72. 2009.

Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med, 2009 Sep 17;361(12):1173-8 Epub 2009 Sep 2. 2009.

Drygin D, Siddiqui-Jain A, O'Brien S, Schwaebe M, Lin A, Bliesath J, Ho CB, Proffitt C, Trent K, Whitten JP, Lim JK, Von Hoff D, Anderes K, Rice WG. Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis. Cancer Res, 2009 Sep 8. [Epub ahead of print]. 2009.

Mahadevan D, Dreisbach L, Kristedja T, Williams D, Obregon Y, Kurtin S, Von Hoff DD. Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies. Am J Clin Oncol, 2009 Jul 10. [Epub ahead of print]. 2009.

Von Hoff DD, Korn R, Mousses S. Pancreatic cancer--could it be that simple? A different context of vulnerability. Cancer Cell, 16(1):7-8. 2009.

Sonpavde G, Galsky MD, Hutson TE, Von Hoff DD. Patient Selection for Phase II Trials. Am J Clin Oncol, 32(2):216-9. 2009.

Galsky MD, Zaks T, Hassani H, Vocila L, Sonpavde G, Hutson TE, Von Hoff DD. Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs, 2009 Mar 6. 2009.

Stephens B, Han H, Hostetter G, Demeure MJ, Von Hoff DD. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol Cancer Ther, Jan;7(1):202-10. 2008.

Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer Pancreas, Mar;36(2):178-86. 2008.

Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H. Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer Mol Cancer Ther., Sep;7(9):3071-80. 2008.

Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-Ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification Cancer Biol Ther, Nov 21;7(11). 2008.

Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol, 31(2):157-62. 2008.

Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, Demeure MJ. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther, 7(2):425-31. 2008.

Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H. Identification of a novel inhibitor of urokinase-type plasminogen activator Mol Cancer Ther, Apr;6(4):1348-56. 2007.

Wang H, Han H, Mousses S, Von Hoff DD. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents Semin Oncol, Aug;33(4):513-20. 2006.

Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach Mol Cancer Ther, Jul;5(7):1764-73.. 2006.

Wang H, Han H, Von Hoff DD. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells Cancer Res, Oct 1;66(19):9722-30. 2006.

Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells Mol Cancer Ther, Oct;5(10):2450-8. 2006.

Hurley LH, Von Hoff DD, Siddiqui-Jain A, Yang D. Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol, 33(4):498-512. 2006.

Von Hoff DD. What's new in pancreatic cancer treatment pipeline?. Best Pract Res Clin Gastroenterol, 20(2):315-26. 2006.

Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer Mol Cancer Ther, Nov;4(11):1653-61. 2005.

Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol, 23(31):7785-93. 2005.

Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol, 16(10):1639-45. 2005.

J. P. Gray, Jr, D. J. Bearss, H. Han, R. Nagle, M. Tsao, N. Dean, and D. D. Von Hoff. Identification of Human Polo-like Kinase 1 as a Potential Therapeutic Target in Pancreatic Cancer. Mol Cancer Ther, 3: 641-646. 2004.

Wang, H., Han, H., Bearss, D., Von Hoff, D.D.. A pharmacological synthetic lethal screening system for the identification of new anti-pancreatic cancer agents specifically targeting DPC4 deficient cells. Proc Am Assoc Cancer Res, 44:5489. 2003.

Han, H., Munoz, R.M., Bearss, D.J., Vankayalapati, H., Nagle, R.B., Hurley, L.H., Von Hoff, D.D.. The urokinase-type plasminogen activator and its receptor as drug targets for pancreatic cancer. Proc Am Assoc Cancer Res, 44:5574. 2003.

Washingon, D., Miller, K., Budd, G.T., Taylor C., Von Hoff, D.D. , Brown, G.L., Parra, R., Jameson, A., Mascavage, J., Henner, W.D.. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) as > third-line therapy in patients with advanced metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 22:61. 2003.

Von Hoff, D.D. , Jolivet, J., Steward, W.. A dose-escalating phase I study of troxacitabine and gemcitabine in advanced solid malignancies. Proc Am Soc Clin Oncol, 22:566. 2003.

Garland, L.L., Gitlitz, B., Ebbinghaus, S., Gately, N., Trammell, J., Von Hoff, D.D. , Figlin, R.. Phase I trial of intravenous IL-4 pseudomonas exotoxin (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. Proc Am Soc Clin Oncol, 22:911. 2003.

Papadimitrakopoulou, V., Figlin, R., Garland, L., Blumenschein, G., Fossella, F., Von Hoff, D.D. , King, L., Brown, G.L., Mascavage, J., Henner, W.D.. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens. Proc Am Soc Clin Oncol, 22:2636. 2003.

S. L. Warner, D. J. Bearss, H. Han, D. D. Von Hoff. Targeting aurora-2 kinase in cancer. Mol. Cancer Ther., 2, 589-595. 2003.

Vankayalapati H, Bearss DJ, Saldanha JW, Munoz RM, Rojanala S, Von Hoff DD. Targeting aurora 2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther, 2(3):283-294. 2003.

H. Han, D. J. Bearss and L. W. Browne, R. Calaluce, R. B. Nagle, D. D. Von Hoff. Identification of Genes Differentially Expressed in Pancreatic Cancer Cells Using cDNA Microarray. Cancer Res., 62, 2890-2896. 2002.

Von Hoff DD, Mahadevan D, Bearss DJ. New developments in the treatment of patients with pancreatic cancer. Clinical Oncology Updates, 4(4):2-15. 2001.

Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, Han FX, Han H, Izbicka E, Von Hoff DD. G-quadruplexes as targets for drug design Pharmacol Ther, Mar;85(3):141-58. 2000.

Von Hoff DD. There Are No Bad Anticancer Agents. Only Bad Clinical Trial Designs – Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res, 4:1079-1086. 1998.

Burris HA III, Moore MJ, Andersen J, Green, MR, Rothenberg, ML, Modiano, MR, Cripps, MC, Portenoy, RK, Storniolo, AM, Tarrassoff, P, Nelson, R, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol, 15(6):2403-13. 1997.